A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Chronic Hepatitis CHepatitis C Virus

Interventions

DRUG

ABT-450/ritonavir (r)

Tablet

DRUG

ABT-530

Tablet

DRUG

Ribavirin (RBV)

Tablet